Products are for professional/laboratory use only. With a comprehensive list of new Single Molecule Counting (SMC™), ELISA and SARS-CoV-2 kits, along with new instruments and xMAP® INTELLIFLEX Calibration and verification kits for RUO.
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
A recent publication in the oncology field revealed that high blood levels of soluble OX40 indicate reduced survival in patients with advanced colorectal cancer (CRC).